Forward-looking statements: this profile is intended to present a summary of ACT's potential platforms. The information contained herein contains "forward-looking statements" as defined under the federal securities laws. Actual results could vary materially. Factors that could cause actual results to vary materially are described in our filings with the Securities and Exchange Commission (for specifics, please see "risk factors" as described in the company's 10K annual filing). The risks identified therein, as well as others not identified by the company, could cause the company's actual results to differ materially from those expressed in any forward-looking statements.

THE COMPANY

Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC) is a biotechnology company developing cellular therapies for the treatment of diseases that impact millions of people worldwide. The company **recently initiated two Phase I/II clinical trials** using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) to treat macular degeneration at UCLA's Jules Stein Eye Institute and also recently received approval from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) to conduct the first hESC trial in Europe. ACT is also developing its **Hemangioblast (HG) platform** for the treatment of blood and cardiovascular diseases, and its Phase II-cleared **Myoblast stem cell therapy** for the treatment of chronic heart failure and other cardiac conditions, and other programs.

ACT's principal laboratory and GMP facility is in Marlborough, Massachusetts, and its corporate offices are in Santa Monica, California. ACT is led by an experienced management team and a world-class scientific team helmed, respectively, by interim chairman and CEO Gary Rabin and chief scientific officer Robert Lanza, M.D.

PATENTS & INTELLECTUAL PROPERTY (IP)

ACT owns or licenses more than 150 patents and patent applications related to stem cell therapy and regenerative medicine, and is positioning itself to have a dominant patent position around its stem cell-derived RPE program in leading markets around the world. A table summarizing two of the company's proprietary technologies follows.

ACT Proprietary Enabling Technology	Description
"Embryo-safe" Blastomere Program	Broad patent on technique
RPE Program	Broad patent on cell production

In 2010 ACT secured three far-reaching patents related to its RPE program, and more recently was issued the first patent for generating hemangioblast cells to treat a broad spectrum of vascular and hematopoietic disorders.

THERAPEUTIC PLATFORMS

The company's RPE and HG programs are hESC-based, and its Myoblast program for cardiac disease is an adult autologous stem cell therapy. As documented in *NATURE* and *Cell Stem Cell*, ACT developed and holds in its repertoire the ***"single-cell blastomere" technique***, the first-ever proven alternative method for successful hESC generation ***without harm to the embryo***, for which it was recently issued a broad patent.

KEY MARKET DATA

Ticker: ACTC.OB

Closing Price 11/08/11: $ 0.11

52-Week Range: $.04 - .27

Market Cap: $177 M

Shares Outstanding: 1.6 B

3-Mth Avg. Daily Volume: 5.7 M

RECENT NEWS & ANNOUNCEMENTS

Nov. 7th - ACT to Host Conference Call on Nov. 9th to Discuss 2011 Third Quarter Results and Provide Update on Clinical Activities

Oct. 18th - European Ruling May Not Impact Stem Cell Lines Derived Using ACT's Single-Blastomere Method

Oct. 5th - Scientific Luminary Dr. Robert Langer Joins ACT's Board of Directors

Oct. 3rd - ACT Chairman and CEO Gary Rabin to Present at World Stem Cell Summit

Sept. 28th - ACT Receives DSMB Approval to Treat Next Patients in Stem Cell Clinical Trials

Sept. 22nd - ACT Receives Approval for First Human Embryonic Stem Cell Trial in Europe

Sept. 19th - ACT Secures First Patent for Generating Hemangioblast Cells to Treat a Broad Spectrum of Vascular and Hematopoietic Disorders

Sept. 8th - Advanced Cell Technology to Present at Two Upcoming Conferences

Aug. 8th ACT Announces 2011 2nd Quarter Results

Aug. 2nd - ACT to Host Conference Call to Discuss 2011 2Q Results, Provide Corporate Update

ADVANCED CELL TECHNOLOGY I SANTA MONICA, CALIFORNIA

RPE Program - ACT has developed a fully-differentiated RPE cell derived from human embryonic stem cells, which can be used as a cellular therapy to treat retinal degenerative diseases. ***ACT recently initiated two Phase I/II clinical trials*** to test the safety of the therapy for Stargardt's Macular Dystrophy (SMD), and for Dry Age-Related Macular Degeneration (Dry AMD). ***Dry AMD represents a $25-30 Billion market in the US and Europe alone,*** and there are no approved therapies currently available for either condition. Two patients have thus far been treated at UCLA, Institutional Review Board (IRB) approval for the SMD clinical trial has also been issued by Oregon Health & Science University (OHSU) and European regulatory clearance has been granted to initiate the first hESC trial in Europe.

Other recent milestones achieved in ACT's RPE program include: the NIH proposed expanding its definition of hESCs for funding purposes, in part to accommodate ACT's lines derived using its patented "embryo-safe" single-cell blastomere technique; and both the FDA and the European Medicines Agency (EMA) granting ACT's RPE cells "Orphan" status for treatment of Stargardt's Disease.

Hemangioblast Program - ACT's Hemangioblast program is for the treatment of blood and cardiovascular diseases. A paper published in *NATURE Methods* revealed the company's successful generation of functional Hemangioblast cells from human embryonic stem cells, and a paper published earlier this year in Cell Research indicated that hESCs could be a potentially unlimited source of platelets for transfusion.

Myoblast Program - ACT's Myoblast treatment may prove particularly beneficial for patients who have experienced a serious heart attack and are at risk for heart failure. ACT has successfully completed Phase I clinical trials and has secured FDA approval to commence with Phase II trials. The Myoblast program has several advantages relative to currently-marketed products and other stem cell therapy approaches, including symptom management and disease modification.

THERAPEUTIC PIPELINE

Proprietary Human Therapeutic Programs	Treatment	Target Market	Clinical Stage	Date	Program Status Recent Milestones
RPE (retinal pigment epithelial) program	Cellular therapies for the treatment of Stargardt's disease (SMD: a form of macular degeneration), dry age-related macular degeneration (Dry AMD) and other degenerative retinal diseases.	> 30-40,000 cases of Stargardt's disease in U.S. > Dry AMD represents $25-30 Billion market in U.S. & Europe alone	Phase I/II Clinical Trials recently initiated.	On-going	Two phase I/II clinical trials initiated at UCLA; IRB approval also issued at OHSU for SMD program; regulatory clearance received for first hESC clinical trial in Europe
Hemangioblast program	Treatment of Diseases and Disorders of the Circulatory and Vascular Systems	> Specific pool to be determined >20 Million cases of heart damaged or dead- heart tissue resulting from heart attack or disease)	Pre-Clinical	2011/2	Published papers showing ability to repair vascular damage in animal models; anticipate IND filing late 2011/early 2012
Myoblast program	Adult stem cell treatment for advanced cardiac disease	> 5 Million cases of heart failure or advanced heart disease U.S.	Cleared to initiate Phase II clinical trial by FDA.	2011/2	FDA-approved to commence with Phase II Clinical Trials; seeking funding

ADVANCED CELL TECHNOLOGY I SANTA MONICA, CALIFORNIA

MANAGEMENT TEAM

- **Gary Rabin, Interim Chairman and Chief Executive Officer –** 23-year career in finance & operations
- **Robert Lanza, MD, Chief Scientific Officer** – 25-year career in biomedical & scientific research
- **Stephen Price, Interim Senior Vice President of Corporate Development** – 16-year career in capital-raising & management
- **Edmund Mickunas, Vice President of Regulatory Affairs** – 28-year career in biotechnology & medical devices
- **Roger Gay, PhD, Senior Director of Manufacturing** – 28-year career in clinical manufacturing & product development
- **Matthew Vincent, PhD, Director of Business Development** – 20-year career in life science deal-making

CONTACT INFORMATION

For more information visit **www.AdvancedCell.com** or feel free to contact,

Company Headquarters
Advanced Cell Technology, Inc.
P.O. Box 1700
Santa Monica, CA 90406
Tel: (310) 576 0611
Fax: (310) 576 0662

Human Resources
careers@advancedcell.com

Massachusetts Facility
33 Locke Dr.
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333

Investor Relations
James Young
jyoung@ceocast.com
(212) 732-4300

Media Relations
Bill Douglass
Gotham Communications, LLC
(646)450-3615
bill@gothamcomm.com

or

Martina Schwarzkopf, Ph.D.
Russo Partners, LLC
(212) 845-4292
martina.schwarzkopf@russopartnersllc.com